Current possibilities of pharmacological correction of neuroimmune joint damage in patients with knee osteoarthritis in long COVID conditions
Objective: to evaluate the efficacy and safety of the parenteral form of pharmaceutical chondroitin sulfate (CS) in neuroimmune joint damage in patients with early knee osteoarthritis (OA) in long COVID.Patients and methods. An open prospective controlled randomized study was conducted, its duration...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Russo |
| Vydáno: |
IMA-PRESS LLC
2022-06-01
|
| Edice: | Современная ревматология |
| Témata: | |
| On-line přístup: | https://mrj.ima-press.net/mrj/article/view/1299 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|